Embryonic Cells Redistribute SUMO1 upon Forced SUMO1 Overexpression

Embryonic stem (ES) cells exhibit unusual transcriptional, proteomic, and signal response profiles, reflecting their unusual needs for rapid differentiation and replication. The work reported here demonstrated that mouse embryonic cell lines did not tolerate the overexpression of SUMO1, the small ubiquitin-like modifier protein that is covalently attached to many substrates to alter their intracellular localization and functionality. Forced SUMO1 overexpression is toxic to ES cells, and surviving cell populations adapt by dramatically reducing the levels of free SUMO1. Such a response is not seen in differentiated cells or with SUMO2 or with nonconjugatable SUMO1 mutants or in the presence of a SUMO1 “sponge” substrate that accepts the modification. The findings suggest that excess SUMO1 modification of specific substrates is not tolerated by embryonic cells and highlight a distinctive need for these cells to control the levels of SUMO1 available for conjugation. ABSTRACT Conjugation of small ubiquitin-like modifiers (SUMOs) to substrate proteins is a posttranslational protein modification that affects a diverse range of physiological processes. Global inhibition of SUMO conjugation in mice results in embryonic lethality, reflecting the importance of the SUMO pathways for embryonic development. Here, we demonstrated that SUMO1 overexpression was not well tolerated in murine embryonic carcinoma and embryonic stem (ES) cells and that only a few clones were recovered after transduction with vectors delivering SUMO1 expression constructs. Differentiated NIH/3T3 cells overexpress SUMO1 without deleterious effects and maintain high levels of both conjugated and free forms of SUMO1. The few embryonic cells surviving after forced overexpression retained all their SUMO1 in the form of a few high-molecular-weight conjugates and maintained undetectable levels of free SUMO1. The absence of free SUMO in embryonic cells was seen specifically upon overexpression of SUMO1, but not SUMO2. Moreover, blocking SUMO1 conjugation to endogenous substrates by C-terminal mutations of SUMO1 or by overexpression of a SUMO1 substrate “sponge” or by overexpression of the deSUMOylating enzyme SUMO-specific peptidase 1 (SENP1) dramatically restored free SUMO1 overexpression. The data suggest that overexpression of SUMO1 protein leading to an excess accumulation of critical SUMO1-conjugated substrates is not tolerated in embryonic cells. Surviving embryonic cells exhibit SUMO1 conjugation to allowed substrates but a complete absence of free SUMO1. IMPORTANCE Embryonic stem (ES) cells exhibit unusual transcriptional, proteomic, and signal response profiles, reflecting their unusual needs for rapid differentiation and replication. The work reported here demonstrated that mouse embryonic cell lines did not tolerate the overexpression of SUMO1, the small ubiquitin-like modifier protein that is covalently attached to many substrates to alter their intracellular localization and functionality. Forced SUMO1 overexpression is toxic to ES cells, and surviving cell populations adapt by dramatically reducing the levels of free SUMO1. Such a response is not seen in differentiated cells or with SUMO2 or with nonconjugatable SUMO1 mutants or in the presence of a SUMO1 “sponge” substrate that accepts the modification. The findings suggest that excess SUMO1 modification of specific substrates is not tolerated by embryonic cells and highlight a distinctive need for these cells to control the levels of SUMO1 available for conjugation.

[1]  A. Vertegaal,et al.  A comprehensive compilation of SUMO proteomics , 2016, Nature Reviews Molecular Cell Biology.

[2]  A. Mund,et al.  KAP1 Is a Host Restriction Factor That Promotes Human Adenovirus E1B-55K SUMO Modification , 2015, Journal of Virology.

[3]  W. Paschen,et al.  SUMO2 is essential while SUMO3 is dispensable for mouse embryonic development , 2014, EMBO reports.

[4]  Xiang-Jiao Yang,et al.  The SUMO Conjugating Enzyme Ubc9 Is Required for Inducing and Maintaining Stem Cell Pluripotency , 2014, Stem cells.

[5]  P. Fraser,et al.  SUMO and Alzheimer’s Disease , 2013, NeuroMolecular Medicine.

[6]  F. Melchior,et al.  Sumoylation: a regulatory protein modification in health and disease. , 2013, Annual review of biochemistry.

[7]  M. Dasso,et al.  Senp1 is essential for desumoylating Sumo1-modified proteins but dispensable for Sumo2 and Sumo3 deconjugation in the mouse embryo. , 2013, Cell reports.

[8]  D. Trono,et al.  The KRAB-ZFP/KAP1 system contributes to the early embryonic establishment of site-specific DNA methylation patterns maintained during development. , 2012, Cell reports.

[9]  Yupo Ma,et al.  Sumoylation Is Important for Stability, Subcellular Localization, and Transcriptional Activity of SALL4, an Essential Stem Cell Transcription Factor* , 2012, The Journal of Biological Chemistry.

[10]  Haibo Wu,et al.  SUMOylation Represses Nanog Expression via Modulating Transcription Factors Oct4 and Sox2 , 2012, PloS one.

[11]  D. Solter,et al.  Trim28 Is Required for Epigenetic Stability During Mouse Oocyte to Embryo Transition , 2012, Science.

[12]  Ji Luo,et al.  A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis , 2012, Science.

[13]  J. Toppari,et al.  Sumo-1 Function Is Dispensable in Normal Mouse Development , 2008, Molecular and Cellular Biology.

[14]  Ming-Ming Zhou,et al.  PHD domain-mediated E3 ligase activity directs intramolecular sumoylation of an adjacent bromodomain required for gene silencing. , 2007, Molecular cell.

[15]  F. Melchior,et al.  Concepts in sumoylation: a decade on , 2007, Nature Reviews Molecular Cell Biology.

[16]  P. Huynh,et al.  Sumoylation of the Transcriptional Intermediary Factor 1β (TIF1β), the Co-repressor of the KRAB Multifinger Proteins, Is Required for Its Transcriptional Activity and Is Modulated by the KRAB Domain* , 2007, Journal of Biological Chemistry.

[17]  E. Yeh,et al.  Characterization of a Family of Nucleolar SUMO-specific Proteases with Preference for SUMO-2 or SUMO-3* , 2006, Journal of Biological Chemistry.

[18]  Pier Paolo Pandolfi,et al.  The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. , 2005, Developmental cell.

[19]  R. Hay,et al.  SUMO: a history of modification. , 2005, Molecular cell.

[20]  K. Khoo,et al.  In Vitro Modification of Human Centromere Protein CENP-C Fragments by Small Ubiquitin-like Modifier (SUMO) Protein , 2004, Journal of Biological Chemistry.

[21]  K. Bohren,et al.  A M55V Polymorphism in a Novel SUMO Gene (SUMO-4) Differentially Activates Heat Shock Transcription Factors and Is Associated with Susceptibility to Type I Diabetes Mellitus* , 2004, Journal of Biological Chemistry.

[22]  Merlin Crossley,et al.  Modification with SUMO , 2003, EMBO reports.

[23]  S. Goff,et al.  Mutations of the RNase H C Helix of the Moloney Murine Leukemia Virus Reverse Transcriptase Reveal Defects in Polypurine Tract Recognition , 2002, Journal of Virology.

[24]  A. Dejean,et al.  c-Jun and p53 Activity Is Modulated by SUMO-1 Modification* , 2000, The Journal of Biological Chemistry.

[25]  G. Blobel,et al.  A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex , 1996, The Journal of cell biology.

[26]  V. Wilson Introduction to Sumoylation. , 2017, Advances in experimental medicine and biology.